Buy this biotech for COVID-19 gains

Article Excerpt

Thermo Fisher’s shares have bounced back from their drop during the March market meltdown. They’re now up 22.1% over the last year. The fundamentals that made Thermo Fisher a good investment before the COVID-19 downturn remain. And now, the company has just received FDA approval for its coronavirus test. From the time it takes to collect a sample to the time it takes to churn out a positive or negative result, that test takes just 4 hours. The demand for scientific, healthcare, and bio-tech products will remain strong. The life sciences industry in particular will continue to see strong growth as the pressure to solve the world’s various health problems grows, along with funding. Meanwhile, Thermo Fisher’s new acquisition Qiagen N.V.—with its strong focus on molecular diagnostics and infectious disease testing—will complement the company’s own specialty diagnostic offerings. In fact, Qiagen’s contributions only strengthen our Power Buy recommendation for this stock. THERMO FISHER SCIENTIFIC INC., $325.83, (New York symbol TMO; TSINetwork Rating: Average) (www.thermofisher.com; Shares outstanding: 395.0 million; Market…